The 2nd option under 'Security' in the tree (Allow active content to run in files on myputer.Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage Meeting Coverage > > Medical News from AACR: American Association for Cancer Research Meeting AACR: COLON CANCER PREVENTION CONTINUES AFTER STOPPING CELECOXIB (CELEBREX) By Charles Bankhead, Staff Writer, MedPage Today Published: April 18, 2008 Reviewed by ; Emeritus Professor University of Pennsylvania School of Medicine.Earn CME/CE credit for reading medical news Use this code to embed video on your website or blog: Explain to interested patients that this study found that the Cox-2 inhibitor celecoxib has effects that seem to protect against colon cancer even after discontinuation of treatment.That celecoxib has cardiovascular side effects and should be used for cancer prevention only after careful discussion with a physician.These findings were reported at a conference as a published abstract and should be considered preliminary until they appear in a peer-reviewed journal."There has been a significant amount of negative press about Cox-2 inhibitors, including celecoxib, and clearly these drugs are risky for some patients," said Dr."However, our study also shows that for patients without major cardiovascular risk factors, celecoxib at low doses protects against high-risk lesions that can lead to colon cancer.The findings came from extended follow-up of patients in the Adenoma Prevention with Celecoxib (APC) trial.Study, which was halted after three years when cardiovascular risks of celecoxib came to light, involved 2,035 adults with a history of multiple or large colorectal adenomas.Participants had been randomized to placebo or to celecoxib at 200 mg or 400 mg twice daily.Colonoscopy was performed at baseline and after one and three years of follow-up.Objective was prevention of sporadic adenomas at the end of the trial.The primary analysis showed that low-dose celecoxib reduced the overall incidence of adenomas by 33% and the occurrence of advanced adenomas by 57%pared with placebo.Celecoxib reduced overall adenoma incidence by 45% and advanced lesions by 66%.Study participants were offered the opportunity to remain in the trial for an additional two years of follow-up off treatment.Read more Reclassification of azithromycin 500mg tablets from pom to p for the treatment of chlamydia, uk
Get more Dipeptidyl peptidase iv inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?
